CIBC Private Wealth Group LLC reduced its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 6.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,710 shares of the biotechnology company’s stock after selling 585 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Sarepta Therapeutics were worth $951,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cornerstone Advisors Inc. acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Oppenheimer Asset Management Inc. acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $51,000. First Quadrant L P CA acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $130,000. Ffcm LLC acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $162,000. Finally, Advisory Research Inc. purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at $214,000. 90.54% of the stock is owned by hedge funds and other institutional investors.
SRPT has been the subject of several analyst reports. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, December 10th. Piper Jaffray Companies upped their target price on Sarepta Therapeutics from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, January 30th. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 19th. Royal Bank of Canada restated an “outperform” rating and issued a $164.00 target price on shares of Sarepta Therapeutics in a report on Thursday, January 17th. Finally, BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Four investment analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average target price of $182.32.
In other news, SVP David T. Howton sold 30,000 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the senior vice president now directly owns 31,196 shares in the company, valued at approximately $4,367,440. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sandesh Mahatme sold 65,000 shares of the stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $145.00, for a total value of $9,425,000.00. Following the transaction, the chief financial officer now owns 73,649 shares of the company’s stock, valued at $10,679,105. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,000 shares of company stock valued at $22,089,950. Company insiders own 7.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4165256/cibc-private-wealth-group-llc-sells-585-shares-of-sarepta-therapeutics-inc-srpt.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Read More: Tariff
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.